Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Europska Unija - hrvatski - EMA (European Medicines Agency)

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - Азацитидин akord indiciran za liječenje odraslih bolesnika koji nemaju pravo na hematopoetski transplantacija matičnih stanica (ТГСК) s:- middleware-2 i visokog rizika миелодиспластические sindroma (mds) prema međunarodnoj prognozu sustav bodovanja (ipss),- kronični миеломоноцитарный leukemije (ХММЛ) s 10-29 % mozgu бластов bez миелопролиферативные poremećaja, akutnog миелоидного leukemije (aml) s 20-30 % бластов i multi-porijeklo displazije, prema podacima svjetske zdravstvene organizacije (who) za klasifikaciju,- aml s >30% бласты koštane srži prema klasifikaciji svjetske zdravstvene organizacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - Азацитидин betapharm indiciran za liječenje odraslih bolesnika koji nemaju pravo na hematopoetski transplantacija matičnih stanica (ТГСК) s:middleware-2 i visokog rizika миелодиспластические sindroma (mds) prema međunarodnoj prognozu sustav bodovanja (ipss),kronični миеломоноцитарный leukemije (ХММЛ) od 10% do 29 % бластов koštane srži, bez миелопролиферативные poremećaja,akutnog миелоидного leukemije (aml) od 20% do 30 % бластов i multi-porijeklo displazije, prema podacima svjetske zdravstvene organizacije (who) za klasifikaciju aml s > 30 % бласты koštane srži prema klasifikaciji svjetske zdravstvene organizacije.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmascience international limited, lampousas, 1, nicosia, cipar - azacitidin - prašak za suspenziju za injekciju - urbroj: jedna bočica s praškom sadrži 100 mg ili 150 mg azacitidina. nakon rekonstitucije 1 ml suspenzije sadrži 25 mg azacitidina.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

stada d.o.o., hercegovačka 14, zagreb, hrvatska - azacitidin - prašak za suspenziju za injekciju - urbroj: svaka bočica s praškom sadrži 100 mg ili 150 mg azacitidina nakon rekonstitucije jedan ml suspenzije sadrži 25 mg azacitidina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - azacitidin - prašak za suspenziju za injekciju - 25 mg/ml - urbroj: svaka bočica s praškom sadrži 100 mg ili 150 mg azacitidina. nakon rekonstitucije jedan ml suspenzije sadrži 25 mg azacitidina.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukemija, mieloidna, akutna - antineoplastična sredstva - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - azacitidin - prašak za suspenziju za injekciju - 25 mg/ml - urbroj: svaka bočica s praškom sadrži 100 mg azacitidina, nakon rekonstitucije jedan ml suspenzije sadrži 25 mg azacitidina